15P Intracranial (IC) efficacy of ivonescimab (ivo) plus chemotherapy (chemo) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated non-small cell lung cancer (NSCLC) in the HARMONi study
Year: 2026
Type: article
Abstract: HARMONi is a global randomized, double-blinded, phase III study evaluating the efficacy and safety of ivo + chemo vs placebo + chemo for patients (pts) with EGFR-mutated NSCLC whose disease has progressed on a 3rd-generation EGFR TKI. In the primary analysis, results showed longer progression-free survival (PFS) with ivo + chemo (hazard ratio [HR], 0.52 [95% confidence interval (CI), 0.41-0.66], P<0.0001) and numerically favorable overall survival (OS) results (HR, 0.79 [95% CI, 0.62-1.01], P=0.0570).
Source: ESMO Open
Institutions: The University of Texas MD Anderson Cancer Center, European Institute of Oncology, Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Hospital General Universitario Gregorio Marañón, Moores Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Toronto, Princess Margaret Cancer Centre, Instituto Nazionale Tumori Regina Elena, Institut Curie, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Sun Yat-sen University Cancer Center, Hunan Cancer Hospital, University of California, Los Angeles, UCLA Health
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,910
OpenAlex ID: W7137991713